Collagenous colitis and atezolizumab therapy: an atypical case
Authors:
Open Access
- 5 November 2020
- journal article
- case report
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 14 (1) , 165-169
Abstract
Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti-PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death protein-ligand 1) are emerging drugs that have radically changed treatment and prognosis of different types of tumors. However, despite their considerable benefits, immune checkpoint inhibitors are associated with numerous side effects involving several organs. Gastrointestinal toxicities represent some of these most common adverse events. While clinical presentation usually ranges from mild diarrhea to life-threatening colitis, typical endoscopic and histologic findings of immune-mediated colitis often resemble those of inflammatory bowel diseases. However, less common patterns are lymphocytic colitis and, rarely, collagenous colitis. Physician and pathologists must be aware of the wide spectrum of clinical and histological findings that may be encountered in immune-related gastro-intestinal toxicities. We report a rare and atypical case of collagenous colitis occurred in a woman affected by stage IV lung adenocarcinoma, on atezolizumab therapy.Keywords
Funding Information
- Università Cattolica del Sacro Cuore
This publication has 12 references indexed in Scilit:
- Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer ImmunotherapyBiomedicine & Pharmacotherapy, 2019
- Immune‐related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsiesHistopathology, 2019
- Immune checkpoint inhibitor-induced colitis: A comprehensive reviewWorld Journal of Clinical Cases, 2019
- Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?Inflammatory Bowel Diseases, 2018
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspectiveJournal of Clinical Pathology, 2018
- Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to managementESMO Open, 2018
- Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 AntibodiesAmerican Journal of Surgical Pathology, 2017
- Current Approach to the Evaluation and Management of Microscopic ColitisCurrent Gastroenterology Reports, 2017
- Anti-PD1-induced collagenous colitis in a melanoma patientMelanoma Research, 2016
- Prevalence and Significance of Inflammatory Bowel Disease-Like Morphologic Features in Collagenous and Lymphocytic ColitisAmerican Journal of Surgical Pathology, 2002